Incyte Corp (INCY):企業の財務・戦略的SWOT分析

◆英語タイトル:Incyte Corp (INCY) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15777
◆発行会社(調査会社):GlobalData
◆発行日:2019年4月
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,375見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,125見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Incyte Corp (INCY) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Incyte Corp (Incyte) is a biopharmaceutical company that discovers, develops, and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis as well as patients with polycythemia vera who are intolerant to hydroxyurea. Jakafi is distributed principally through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Norvatis) develops and commercializes ruxolitinib outside the US for hematologic and oncologic indications under the name Jakavi. The company’s pipeline portfolio encompasses drug indications targeted at the treatment of lung cancer, graft versus host disease, non-small cell lung cancer, multiple tumor types, b-cell malignancies, solid tumors, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.

Incyte Corp Key Recent Developments

Apr 01,2019 Merus and Incyte Present MCLA-145 Program Preclinical Data
Apr 01,2019 Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019
Mar 20,2019 PRNewswire Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China December 16, 2018
Feb 28,2019 Incyte Joins Patient Organizations Worldwide in Recognizing Rare Disease Day 2019

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Incyte Corp – Key Facts
Incyte Corp – Key Employees
Incyte Corp – Key Employee Biographies
Incyte Corp – Major Products and Services
Incyte Corp – History
Incyte Corp – Company Statement
Incyte Corp – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Incyte Corp – Business Description
Product Category: Iclusig
Performance
Product Category: Jakafi
Performance
Product Category: Jakavi Product Royalty Revenue
Performance
Product Category: Milestone and Contract Revenue
Performance
Product Category: Olumiant Product Royalty Revenues
Performance
Product Category: Other Revenue
Performance
R&D Overview
Incyte Corp – Corporate Strategy
Incyte Corp – SWOT Analysis
SWOT Analysis – Overview
Incyte Corp – Strengths
Incyte Corp – Weaknesses
Incyte Corp – Opportunities
Incyte Corp – Threats
Incyte Corp – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Incyte Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 01, 2019: Merus and Incyte Present MCLA-145 Program Preclinical Data
Apr 01, 2019: Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019
Mar 20, 2019: PRNewswire Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China December 16, 2018
Feb 28, 2019: Incyte Joins Patient Organizations Worldwide in Recognizing Rare Disease Day 2019
Jan 03, 2019: Incyte appoints Christiana Stamoulis as chief financial officer
Dec 18, 2018: Incyte agrees to licence three products to Innovent Biologics
Nov 27, 2018: Incyte names Dr. Dashyant Dhanak as Chief Scientific Officer
Nov 27, 2018: Incyte Appoints Dr. Dashyant Dhanak as Chief Scientific Officer
Nov 01, 2018: Multiple Abstracts Highlighting Data from Incyte’s Targeted Therapy Portfolio Accepted for Presentation at the 60th Annual ASH Meeting
Oct 25, 2018: FDA Grants Priority Review for Ruxolitinib (Jakafi ) as a Treatment for Patients with Acute Graft-Versus-Host Disease
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Incyte Corp, Key Facts
Incyte Corp, Key Employees
Incyte Corp, Key Employee Biographies
Incyte Corp, Major Products and Services
Incyte Corp, History
Incyte Corp, Subsidiaries
Incyte Corp, Key Competitors
Incyte Corp, Ratios based on current share price
Incyte Corp, Annual Ratios
Incyte Corp, Annual Ratios (Cont...1)
Incyte Corp, Annual Ratios (Cont...2)
Incyte Corp, Interim Ratios
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Incyte Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Incyte Corp, Performance Chart (2014 - 2018)
Incyte Corp, Ratio Charts
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Incyte Corp, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Incyte Corp (INCY):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cabot Oil & Gas Corporation (COG):企業のM&A・提携動向(石油・ガス分野)
    Summary Cabot Oil & Gas Corporation (Cabot) is an independent oil and gas company, which develops, and explores for oil and gas properties primarily in the continental US. It focuses on developing natural gas resources in the Marcellus shale in northeast Pennsylvania and oil development in the Eagle …
  • Abu Dhabi National Insurance Company PSC:企業の戦略・SWOT・財務分析
    SummaryAbu Dhabi National Insurance Company PSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of …
  • Can-Fite BioPharma Ltd. (CFBI)(製薬・医療分野):企業M&A動向
    Summary Can-Fite BioPharma Ltd. (Can-Fite) is a biopharmaceutical company. It undertakes the discovery and clinical development of pharmaceutical products utilizing its platform technology. The company focuses on developing drugs that are used in the treatment of diseases such as cancer, sexual dysf …
  • Odfjell SE (ODF):企業のM&A・提携動向(石油・ガス分野)
    Summary Odfjell SE (Odfjell) is an independent shipping company, which carries out the transportation and storage of bulk liquid organic and inorganic chemicals, edible oils and clean petroleum products and lubricating oils. Odfjell owns and operates chemical tankers and LPG/Ethylene carriers in glo …
  • United Technologies Corporation:戦略・SWOT・企業財務分析
    United Technologies Corporation - Strategy, SWOT and Corporate Finance Report Summary United Technologies Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Laborie Medical Technologies Inc:企業のM&A・提携動向(医療機器分野)
    Summary Laborie Medical Technologies Inc (Laborie) is a medical device company that manufactures and markets pelvic health and gastrointestinal equipment and consumables. The company’s urology and urogynecology products include uroflowmetry, urodynamics, pelvic floor rehabilitation, anorectal manome …
  • Agilent Technologies, Inc. (A):企業のM&A・提携動向(医療機器分野)
    Summary Agilent Technologies, Inc. (Agilent) is a provider of instruments, reagents, software, services and consumables to diagnostics, life sciences and applied chemical markets for comprehensive laboratory workflow. Its product portfolio comprises atomic absorption systems, bioanalyzers, gene expr …
  • American Tower Corporation:企業のM&A・提携・投資分析
    American Tower Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's American Tower Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Genelux Corporation(製薬・医療分野):企業M&A動向
    Summary Genelux Corporation (Genelux) is a clinical stage biopharmaceutical company. The company develops and commercializes diagnostic and therapeutic solutions for the treatment of cancer and inflammatory diseases. Its product pipeline includes GL-ONC1, GL-ONC2, GL-ONC3, GL-ONC4, GL-IMG2 and V-VET …
  • Jilin Zixin Pharmaceutical Ind. Co., Ltd (002118):企業の財務及び戦略的SWOT分析
    Summary Jilin Zixin Pharmaceutical Industrial Co., Ltd. (Jilin Zixin) is a pharmaceutical company that offers research and development services. The company research, develops, manufactures and sells traditional Chinese patent drugs, and the plantation of medicinal materials. Its products include Hu …
  • Pine Cliff Energy Ltd. (PNE):企業財務及び戦略的SWOT分析
    Summary Pine Cliff Energy Ltd. (Pine Cliff) is an oil and gas company that focuses on the exploration, development and production of crude oil, natural gas and natural gas liquids. The company operates through its core areas such as Central Assets, Edson Assets and Southern Assets. It acquired Hatto …
  • Asiri Hospital Holdings PLC (ASIR.N0000):企業財務及び戦略的SWOT分析
    Summary Asiri Hospital Holdings PLC (Asiri) is a healthcare service company that offers medical investigations and diagnosis. The company provides critical care wards, neonatal intensive care unit, fully computerized modern pathology laboratory, nine bedded intensive care unit, e-channeling consulta …
  • Greenvision Ambiente S.p.A.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Greenvision Ambiente S.p.A. Mer …
  • Elan Corporation, plc:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Elan Corporation, plc Mergers a …
  • Hospira, Inc. (HSP):企業のM&A・提携動向(医療機器分野)
    Summary Hospira, Inc. (Hospira) is a global specialty pharmaceutical and medication delivery company. It undertakes manufactures and markets products that help improve the safety and effectiveness and reduce the cost of patient care. The company is a provider of injectable pharmaceutical drugs and i …
  • Anadarko Petroleum Corporation:企業のM&A・提携・投資分析
    Anadarko Petroleum Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Anadarko Petroleum Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Asahi Kasei Corporation (3407):企業のM&A・提携動向(エネルギー分野)
    Summary Asahi Kasei Corporation (Asahi Kasei), formerly Asahi Chemical Industry Co. Ltd., is a holding company of Asahi Kasei Group. The company’s product portfolio includes polymers, acrylonitrile, caustic soda, styrene, diagnostic reagents, nutritional products, contact lenses, medical devices and …
  • Cosway Company Inc. :企業の戦略・SWOT・財務分析
    SummaryCosway Company Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Fin …
  • Polaris Infrastructure Inc. (PIF):企業のM&A・提携動向(発電分野)
    Summary Polaris Infrastructure Inc. (Polaris Infrastructure), formerly Ram Power, Corp. is a renewable energy company that acquires, explores, develops and operates geothermal energy projects. The company owns and operates San Jacinto Project, which is located in northwest Nicaragua, near the city o …
  • GPS Source, Inc.:企業の戦略・SWOT・財務分析
    SummaryGPS Source, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆